[1] World Health Organization. Global tuberculosis report 2015. Geneva: World Health Organization, 2015. [2] He GX, Zhao YL, Jiang GL, Liu YH, Xia H, Wang SF, Wang LX, Borgdorff MW, van der Werf MJ, van den Hof S. Prevalence of tuberculosis drug resistance in 10 provinces of China. BMC Infect Dis , 2008, 8(1): 166. [3] Zhao YL, Xu SF, Wang LX, Chin DP, Wang SF, Jiang GL, Xia H, Zhou Y, Li Q, Ou XC, Pang Y, Song YY, Zhao B, Zhang HT, He GX, Guo J, Wang Y. National survey of drug-resistant tuberculosis in China. N Engl J Med , 2012, 366(23): 2161-2170. [4] Gonzalo X, Hutchison DC, Drobniewski FA, Pimkina E, Davidaviciene E. Multidrug-resistant tuberculosis in the United Kingdom and Lithuania. Int J Tuberc Lung Dis , 2014, 18(6): 663-665. [5] Zhang ZJ, Wang YG, Pang Y, Kam KM. Ethambutol resistance as determined by broth dilution method correlates better than sequencing results with embB mutations in multidrug-resistant Mycobacterium tuberculosis isolates. J Clin Microbiol , 2014, 52(2): 638-641. [6] Chen QY, Pang Y, Liang QF, Lin SF, Wang YF, Lin J, Zhao Y, Wei SZ, Zheng JF, Zheng SH. Molecular characteristics of MDR Mycobacterium tuberculosis strains isolated in Fujian, China. Tuberculosis , 2014, 94(2): 159-161. [7] Shi DW, Li L, Zhao YL, Jia Q, Li H, Coulter C, Jin Q, Zhu GF. Characteristics of embB mutations in multidrug- resistant Mycobacterium tuberculosis isolates in Henan, China. J Antimicrob Chemother , 2011, 66(10): 2240-2247. [8] Chatterjee D. The mycobacterial cell wall: structure, biosynthesis and sites of drug action. Curr Opin Chem Biol , 1997, 1(4): 579-588. [9] Jankute M, Grover S, Rana AK, Besra GS. Arabinogalactan and lipoarabinomannan biosynthesis: structure, biogenesis and their potential as drug targets. Future Microbiol , 2012, 7(1): 129-147. [10] Srivastava S, Ayyagari A, Dhole TN, Nyati KK, Dwivedi SK. emb nucleotide polymorphisms and the role of embB 306 mutations in Mycobacterium tuberculosis resistance to ethambutol. Int J Med Microbiol , 2009, 299(4): 269-280. [11] Ramaswamy SV, Amin AG, Göksel S, Stager CE, Dou SJ, El Sahly H, Moghazeh SL, Kreiswirth BN, Musser JM. Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother , 2000, 44(2): 326-336. [12] Ahmad S, Jaber AA, Mokaddas E. Frequency of embB codon 306 mutations in ethambutol-susceptible and-resistant clinical Mycobacterium tuberculosis isolates in Kuwait. Tuberculosis , 2007, 87(2): 123-129. [13] Mokrousov I, Otten T, Vyshnevskiy B, Narvskaya O. Detection of embB306 mutations in ethambutol-susceptible clinical isolates of Mycobacterium tuberculosis from northwestern Russia: implications for genotypic resistance testing. J Clin Microbiol , 2002, 40(10): 3810-3813. [14] Hazbón MH, Bobadilla del Valle M, Guerrero MI, Varma-Basil M, Filliol I, Cavatore M, Colangeli R, Safi H, Billman-Jacobe H, Lavender C, Fyfe J, García-García L, Davidow A, Brimacombe M, León CI, Porras T, Bose M, Chaves F, Eisenach KD, Sifuentes-Osornio J, Ponce de León A, Cave MD, Alland D. Role of embB codon 306 mutations in Mycobacterium tuberculosis revisited: a novel association with broad drug resistance and IS 6110 clustering rather than ethambutol resistance. Antimicrob Agents Chemother , 2005, 49(9): 3794-3802. [15] Madison B, Robinson-Dunn B, George I, Gross W, Lipman H, Metchock B, Sloutsky A, Washabaugh G, Mazurek G, Ridderhof J. Multicenter evaluation of ethambutol susceptibility testing of Mycobacterium tuberculosis by agar proportion and radiometric methods. J Clin Microbiol , 2002, 40(11): 3976-3979. [16] Safi H, Sayers B, Hazbón MH, Alland D. Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid, and rifampin. Antimicrob Agents Chemother , 2008, 52(6): 2027-2034. [17] Cuevas-Córdoba B, Juárez-Eusebio DM, Almaraz-Velasco R, Muñiz-Salazar R, Laniado-Laborin R, Zenteno-Cuevas R. Mutation at embB codon 306, a potential marker for the identification of multidrug resistance associated with ethambutol in Mycobacterium tuberculosis . Antimicrob Agents Chemother , 2015, 59(9): 5455-5462. [18] Feng Y, Liu SJ, Wang QG, Wang L, Tang SW, Wang JM, Lu W. Rapid diagnosis of drug resistance to fluoroquinolones, amikacin, capreomycin, kanamycin and ethambutol using genotype MTBDRsl assay: a meta-analysis. PLoS One , 2013, 8(2): e55292. [19] Parsons LM, Salfinger M, Clobridge A, Dormandy J, Mirabello L, Polletta VL, Sanic A, Sinyavskiy O, Larsen SC, Driscoll J, Zickas G, Taber HW. Phenotypic and molecular characterization of Mycobacterium tuberculosis isolates resistant to both isoniazid and ethambutol. Antimicrob Agents Chemother , 2005, 49(6): 2218-2225. [20] Srivastava S, Garg A, Ayyagari A, Nyati KK, Dhole TN, Dwivedi SK. Nucleotide polymorphism associated with ethambutol resistance in clinical isolates of Mycobacterium tuberculosis . Curr Microbiol , 2006, 53(5): 401-405. [21] Safi H, Fleischmann RD, Peterson SN, Jones MB, Jarrahi B, Alland D. Allelic exchange and mutant selection demonstrate that common clinical embCAB gene mutations only modestly increase resistance to ethambutol in Mycobacterium tuberculosis . Antimicrob Agents Chemother , 2010, 54(1): 103-108. [22] Safi H, Lingaraju S, Amin A, Kim S, Jones M, Holmes M, McNeil M, Peterson SN, Chatterjee D, Fleischmann R, Alland D. Evolution of high-level ethambutol-resistant tuberculosis through interacting mutations in decaprenylphosphoryl-β-D-arabinose biosynthetic and utilization pathway genes. Nat Genet , 2013, 45(10): 1190-1197. [23] Brossier F, Sougakoff W, Bernard C, Petrou M, Adeyema K, Pham A, Amy de la Breteque D, Vallet M, Jarlier V, Sola C, Veziris N. Molecular analysis of the embCAB locus and embR gene involved in ethambutol resistance in clinical isolates of Mycobacterium tuberculosis in France. Antimicrob Agents Chemother , 2015, 59(8): 4800-4808. [24] Cui ZL, Li YY, Cheng S, Yang H, Lu JM, Hu ZY, Ge BX. Mutations in the embC-embA intergenic region contribute to Mycobacterium tuberculosis resistance to ethambutol. Antimicrob Agents Chemother , 2014, 58(11): 6837-6843. [25] Belanger AE, Besra GS, Ford ME, Mikusová K, Belisle JT, Brennan PJ, Inamine JM. The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc Natl Acad Sci USA , 1996, 93(21): 11919-11924. [26] He L, Wang XB, Cui P, Jin JL, Chen JZ, Zhang WH, Zhang Y. ubiA (Rv3806c) encoding DPPR synthase involved in cell wall synthesis is associated with ethambutol resistance in Mycobacterium tuberculosis . Tuberculosis , 2015, 95(2): 149-154. [27] Moure R, Español M, Tudó G, Vicente E, Coll P, Gonzalez-Martin J, Mick V, Salvadó M, Alcaide F. Characterization of the embB gene in Mycobacterium tuberculosis isolates from Barcelona and rapid detection of main mutations related to ethambutol resistance using a low-density DNA array-authors' response. J Antimicrob Chemother , 2014, 69(8): 2299-2300. [28] Xu YH, Jia HY, Huang HR, Sun ZG, Zhang ZD. Mutations found in embCAB , embR , and ubiA genes of ethambutol-sensitive and -resistant Mycobacterium tuberculosis clinical isolates from China. BioMed Res Int , 2015, 2015: 951706. [29] Park YK, Ryoo SW, Lee SH, Jnawali HN, Kim CK, Kim HJ, Kim SJ. Correlation of the phenotypic ethambutol susceptibility of Mycobacterium tuberculosis with embB gene mutations in Korea. J Med Microbiol , 2012, 61(4): 529-534. [30] Sreevatsan S, Stockbauer KE, Pan X, Kreiswirth BN, Moghazeh SL, Jacobs WR Jr, Telenti A, Musser JM. Ethambutol resistance in Mycobacterium tuberculosis : critical role of embB mutations. Antimicrob Agents Chemother , 1997, 41(8): 1677-1681. [31] Plinke C, Cox HS, Zarkua N, Karimovich HA, Braker K, Diel R, Rüsch-Gerdes S, Feuerriegel S, Niemann S. embCAB sequence variation among ethambutol-resistant Mycobacterium tuberculosis isolates without embB 306 mutation. J Antimicrob Chemother , 2010, 65(7): 1359-1367. [32] Liu H, Xie JP. Comparative genomics of Mycobacterium tuberculosis drug efflux pumps and their transcriptional regulators. Crit Rev Eukaryot Gene Expr , 2014, 24(2): 163-180. [33] Pei H, Zhang SL, Liu J, Dai YX, Huang B, Wang X, Hu MT, Kuai SG, Wang K. The role of ABC efflux pump, Rv1456c-Rv1457c-Rv1458c, from Mycobacterium tuberculosis clinical isolates in China. Folia Microbiol , 2011, 56(6): 549-553. [34] Spivey VL, Whalan RH, Hirst EM, Smerdon SJ, Buxton RS. An attenuated mutant of the Rv1747 ATP-binding cassette transporter of Mycobacterium tuberculosis and a mutant of its cognate kinase, PknF, show increased expression of the efflux pump-related iniBAC operon. FEMS Microbiol Lett , 2013, 347(2): 107-115. [35] Gupta AK, Reddy VP, Lavania M, Chauhan DS, Venkatesan K, Sharma VD, Tyagi AK, Katoch VM. jefA (Rv2459), a drug efflux gene in Mycobacterium tuberculosis confers resistance to isoniazid & ethambutol. Indian J Med Res , 2010, 132(2): 176-188. [36] Pule CM, Sampson SL, Warren RM, Black PA, van Helden PD, Victor TC, Louw GE. Efflux pump inhibitors: targeting mycobacterial efflux systems to enhance TB therapy. J Antimicrob Chemother , 2016, 71(1): 17-26. [37] Xie LX, Yu ZX, Guo SY, Li P, Abdalla AE, Xie JP. The roles of epigenetics and protein post-translational modifications in bacterial antibiotic resistance. Hereditas ( Beijing ), 2015, 37(8): 793-800. 谢龙祥, 于召箫, 郭思瑶, 李萍, Abdalla AE, 谢建平. 表观遗传和蛋白质翻译后修饰在细菌耐药中的作用. 遗传, 2015, 37(8): 793-800. |